LOS GATOS, CA - Tenon Medical, Inc. (NASDAQ:TNON), a company specializing in surgical and medical instruments, announced the results of its 2024 Annual Stockholders Meeting held on Tuesday. Shareholders voted on several key proposals, including the election of board members, amendments to the company's equity plan, and the ratification of its independent auditor.
The meeting, which took place virtually, saw the election of seven nominees to the company’s Board of Directors. Each director will serve until the 2025 annual meeting or until their successor is elected. The directors elected are Richard Ferrari (NYSE:RACE), Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle.
In addition to board elections, shareholders approved the terms of the company's Series B Preferred Stock, the related warrants, and an amendment to the terms of the Series A Preferred Stock to decrease the conversion price. This move was made to comply with the Nasdaq Listing Rule 5635(d).
Another significant development from the meeting was the approval of amendments to the Tenon Medical, Inc. 2022 Equity Incentive Plan. The amendments include an increase of 1,100,000 shares of common stock subject to the plan and the ability to issue equity awards to individuals and legal entities.
Furthermore, the appointment of Haskell & White LLP as Tenon Medical's independent auditor for the fiscal year ending December 31, 2024, was ratified. The selection by the Board of Directors received a majority vote in favor.
The turnout for the meeting represented approximately 57.33% of the outstanding voting shares, which constituted a quorum as per the Delaware General Corporation Law and the bylaws of the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.